Why the study?
Is low-dose ticagrelor safe and feasible in patients with STEMI based on PAR monitoring?
Is low-dose ticagrelor safe and feasible in patients with STEMI based on PAR monitoring?
Low-dose ticagrelor appears safe and feasible in STEMI patients when guided by platelet reactivity monitoring.
Answers are grounded in this paper and cite their sources.
Low-dose ticagrelor may be feasible in STEMI with PAR monitoring; hypothesis-generating and requires randomized confirmation before practice change.
It is safe and feasible of low-dose ticagrelor for patients with STEMI based on the monitoring of PAR.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: